Učitavanje...
Risk of cardiovascular events among patients with HIV treated with atazanavir-containing regimens: a retrospective cohort study
BACKGROUND: A previous cohort study indicated that atazanavir (ATV), a protease inhibitor used for HIV treatment, is not associated with an increased risk of cardiovascular (CV) events. The objective of this study was to compare the risk of CV events among antiretroviral-naïve patients initiating AT...
Spremljeno u:
| Izdano u: | BMC Infect Dis |
|---|---|
| Glavni autori: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5028993/ https://ncbi.nlm.nih.gov/pubmed/27643691 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12879-016-1827-1 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|